Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOZORAKIMAB (MEDI3506) IN PATIENTS HOSPITALISED FOR VIRAL LUNG INFECTION REQUIRING SUPPLEMENTAL OXYGEN (TILIA)

Intervention/treatment:
TOZORAKIMAB (MEDI3506)
Medical condition:
LUNG INJURY
Protocol code:
D9185C00001
Control number:
268618
Status:
Recruiting
Approved:
November 09, 2022
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05624450
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Alberta

Research Site
Calgary, Alberta, T2N 1N4
Recruiting

British Columbia

Research Site
New Westminster, British Columbia, V3L 3W7
WITHDRAWN

Manitoba

Research Site
Winnipeg, Manitoba, R2H 2A6
WITHDRAWN
Research Site
Winnipeg, Manitoba, R3A 1R9
WITHDRAWN
Research Site
Winnipeg, Manitoba, R3J 3M7
WITHDRAWN

Ontario

Research Site
Brampton, Ontario, L6R 3J9
Recruiting
Research Site
Ottawa, Ontario, K1H 8L6
Recruiting
Research Site
Ottawa, Ontario, K1Y 4E9
Recruiting
Research Site
Toronto, Ontario, M4N 3M5
Recruiting

Quebec

Research Site
Lévis, Quebec, G6V 3Z1
Recruiting
Research Site
Montreal, Quebec, H1T 2M4
Recruiting
Research Site
Montreal, Quebec, H2W 1S6
Recruiting
Research Site
Montreal, Quebec, H2X 3E4
Recruiting
Research Site
Québec, Quebec, G1V 4G5
Recruiting

Saskatchewan

Research Site
Saskatoon, Saskatchewan, S7N 0W8
Recruiting
Did you find what you were looking for?